Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 6 % of short-term debt in 2024; threshold 65 %.
Financials
Financial year 2024
M-Pharma from Antwerpen, company number BE0678937543, closed financial year 2024 with a result of € -264,618 after tax. For that financial year M-Pharma recorded revenue of € 257,939 and equity of € -231,686. Compared with financial year 2023, the result moved from € -105,927 to € -264,618. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 22, 2025.
€ -231,686
▼ € 264,618 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -264,618
▼ 150 % more loss than in 2023
Profit after tax over the fiscal year.
€ 1,122
▼ 72% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1 million.
People and assets in 2024
€ 127,617
▲ 82% vs 2023
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 64,500
▲ € 53,796 vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 61,750
▲ € 53,598 vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 302,460 | € 291,585 | - | € 257,939 | |
| Gross margin | € -85,079 | € -80,599 | € -44,212 | € -141,987 | ▼ € 97,775 |
| Profit after taxes | € -141,441 | € -133,875 | € -105,927 | € -264,618 | ▼ € 158,691 |
| Equity | € 272,733 | € 138,858 | € 32,932 | € -231,686 | ▼ € 264,618 |
| Total debts | € 35,170 | € 58,690 | € 18,855 | € 247,565 | ▲ € 228,710 |
| Cash | € 5,570 | € 4,805 | € 3,962 | € 1,122 | ▼ 72% |
| Retained profit | € -495,867 | € -629,742 | € -735,668 | € -1,000,286 | ▼ € 264,618 |
| Balance sheet total | € 307,903 | € 197,549 | € 51,787 | € 15,879 | ▼ 69% |
| Employees (FTE) | - | - | 0.9 | - |
Key figures of M-Pharma, fiscal years 2022 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to M-Pharma?
What happened at M-Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 264,618. filed late Source: NBB ↗
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 141,441 loss in 2022 to € 264,618 loss in 2024.
A new publication or filing at M-Pharma? We notify you, reason included.
Follow M-PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind M-Pharma are Hubertus Cornelus Verhoef, Aalbertus Gijsbert Rik Van De Weerd and Erik August Heuthorst. Aalbertus Gijsbert Rik Van De Weerd is also behind Mercurius Holding. Erik August Heuthorst is also behind Mercurius Holding.
Directors
According to the 2024 annual accounts
Hubertus Cornelus Verhoef
Director
Establishments
Establishment units
Physical locations of this company
Borsbeeksebrug 30
2600 Antwerpen
Prinses Clementinalaan 16
9000 Gent
Active since 27 July 2017
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →Kuehne + Nagel
€ 563.7 million revenue · 2025
KRUIDVAT
€ 715.5 million revenue · 2024
Kuehne + Nagel Fulfillment
€ 20.7 million revenue · 2025
NACORA INSURANCE BROKERS
€ 1.1 million revenue · 2025
Teleperformance Belgium
€ 9.5 million gross margin · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0678.937.543
- VAT number
- BE 0678.937.543
- Registered office
- Borsbeeksebrug 30, 2600 Antwerpen
- Names & denominations
- M-Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 July 2017
- Peppol
- Active · Active since 18 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten